TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intra-articular Polyacrylamide Hydrogel in the Treatment of Gonarthrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria for the IA/PAAG-SI/OA/2019 study~1. Men and women over 50 years old;~2. Verified gonarthrosis according to the ACR criteria (knee pain in combination with one of the following signs: age over 50 years, crepitus in the joint or morning stiffness in the joint lasting less than 30 minutes in combination with radiographic signs of gonarthrosis);~3. II-III radiographic stage of gonarthrosis according to the Kellgren-Lawrence classification with predominant damage to the medial tibiofemoral region of the knee joint;~4. Radiographic joint space width (JSW) of the target knee joint of at least 2.5 mm.~Inclusion criteria for the IA/PAAG-SI/OA/2020 study~1. Men and women over 50 years of age;~2. Signed informed consent form by the study participant;~3. Verified gonarthrosis according to the ACR criteria (knee pain in combination with one of the following: age over 50 years, crepitus in the joint or morning stiffness in the joint lasting less than 30 minutes in combination with radiographic signs of gonarthrosis);~4. II-III radiographic stage of gonarthrosis according to the Kellgren-Lawrence classification with predominant damage to the medial tibiofemoral region of the knee joint Completion of participation in the clinical study IA/PAAG-SI/OA/2019 in the NOLTREX™ medical device group with the completion of visit 5 procedures (25 weeks).~Exclusion criteria N/A

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with primary humoral immunodeficiency, namely with a diagnosis of Common variable immunodeficiency (CVID) as defined by the Pan-American Group for Immunodeficiency (PAGID) and the European Society for Immunodeficiencies (ESID), or X-linked agammaglobulinemia (XLA) as defined by PAGID and ESID, or autosomal recessive agammaglobulinemia who have participated in the study ZLB06_001CR and who have tolerated IgPro well~* Written informed consent~Exclusion Criteria:~* Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (defined as total urine protein concentration \> 0.2g/L)~* Other significant medical conditions that could increase the risk to the subject~* Females who are pregnant, breast feeding or planning a pregnancy during the course of the study~* Participation in a study with an investigational medicinal product within three months prior to enrollment, except for ZLB06_001CR~* Evidence of uncooperative attitude~* Any condition that is likely to interfere with evaluation of the IMP or satisfactory conduct of the study~* Subjects who are employees at the investigational site, relatives or spouse of the investigator

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- IgPro20 (Type: EXPERIMENTAL): Subcutaneous (SC) administration by the subject/parent/guardian with the planned weekly dose of IgPro20 to be the same as the subject's last dose recommended by the investigator in study ZLB06_001CR (NCT00542997).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Consenting patients were eligible for enrollment if they:~  1. were 18-65 years of age,~ 2. had endoscopically diagnosed active duodenal ulcers within the previous 72 hours,~ 3. the number of ulcers was at least one, but no more than two with the larger diameter 0.3-2.0cm.~Exclusion Criteria:~* Patients were ineligible if they:~  1. had cancerous or complex ulcers, Zollinger-Ellison syndrome, esophageal erosion or ulcer, varices of esophagus or fundus of stomach, or pyloric stenosis,~ 2. had a known history of gastric acid suppression operation, esophageal operation or peptic operation other than simple closure of perforation,~ 3. had severe complications (e.g., pyloric obstruction, active bleeding under endoscope), severe other diseases of digestive tract such as Crohn's disease and ulcerative colitis, and severe other systemic diseases,~ 4. were female patients who were breast feeding, pregnant, or intended to become pregnant during the study,~ 5. had taken proton pump inhibitors within the 5 days or for more than three consecutive days within the two weeks immediately preceding start of study drug,~ 6. participated in a clinical trial with an investigational drug or device within the past three months,~ 7. had hypersensitivity or idiosyncratic reaction to omeprazole or any other benzimidazole,~ 8. had alcoholic intemperance, drug addiction or any other improper habits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 5 mg ilaprazole (Type: EXPERIMENTAL): None
- 10 mg ilaprazole (Type: EXPERIMENTAL): None
- 20 mg ilaprazole (Type: EXPERIMENTAL): None
- 20 mg omeprazole (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel-bevacizumab in Advanced Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 2nd or 3rd line of non squamous non small cell lung cancer of stage III or IV~* Document progression at the time of the inclusion. At least, one previous chemotherapy line with platinum. Patient who had previous treatment with bevacizumab can be included.~* Patient with active mutation of EGFR must have had on line of chemotherapy with platinum and one with Tyrosine kinase inhibitor of EGFR.~* Patient with ALK rearrangement must have had at least one line of chemotherapy with platinum and one with crizotinib.~Exclusion Criteria:~* Mixed cancer small cells and non small cells or squamous lung cancer.~* Central nervous system symptomatic metastasis or requiring immediate cerebral radiotherapy~* patient who have had previous treatment with taxane (docetaxel, paclitaxel). Peri-operatory chemotherapy or chemoradiotherapy with taxane allowed if stopped more than 6 months before.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel (Type: ACTIVE_COMPARATOR): None
- Paclitaxel - Bevacizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Postmenopausal women who meet at least one of the following bone mineral density (BMD) and fracture criteria:~* BMD T-score at the total hip or femoral neck of ≤ -2.50 and EITHER:~  * at least 1 moderate (semiquantitative grade \[SQ\]2) or severe (SQ3) vertebral fracture OR~ * at least 2 mild (SQ1) vertebral fractures OR~* BMD T-score at the total hip or femoral neck of ≤ -2.00 and EITHER:~  * at least 2 moderate (SQ2) or severe (SQ3) vertebral fractures OR~ * a fracture of the proximal femur that occurred within 3 to 24 months prior to randomization.~Exclusion Criteria:~* History of metabolic or bone disease (except osteoporosis)~* Use of agents affecting bone metabolism~* Vitamin D insufficiency~* History of solid organ or bone marrow transplants~* Hyper- or hypocalcemia~* Hyper- or hypothyroidism~* Hyper- or hypoparathyroidism~* Possible signs of intolerance to alendronate

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Alendronate/Alendronate (Type: ACTIVE_COMPARATOR): Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.
- Romosozumab/Alendronate (Type: EXPERIMENTAL): Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meets Axis I diagnosis criteria for Conduct Disorder or Oppositional Defiant Disorder or Disruptive Behavior Disorder not otherwise specified (DSM-IV, Diagnostic and Statistical Manual of Mental Diseases, 4th edition) and has a total rating of \>=24 on the Nisonger Child Behavior Rating Form (N-CBRF) Conduct Problem Subscale. (Patients with conduct disorder who also meet DSM-IV criteria for Attention Deficit/Hyperactivity Disorder (AD/HD) are eligible.)~* meets DSM-IV Axis II diagnosis criteria for Mild Mental Retardation, Moderate Mental Retardation or Borderline Intellectual Functioning (diagnoses that represent intelligence quotients \[IQs\] ranging from 35 to 84)~Exclusion Criteria:~* DSM-IV diagnosis of Pervasive Development Disorder, Schizophrenia, or Other Psychotic Disorders~* head injury as cause of mental impairment~* seizure disorder currently requiring medication~* history of tardive dyskinesia (a condition of uncontrollable movements of the tongue, lips, face, trunk, hands and feet that is seen in patients receiving long-term medication with certain types of antipsychotic drugs) or neuroleptic malignant syndrome (a rare psychotropic-drug reaction, which may be characterized by confusion, reduced consciousness, high fever or pronounced muscle stiffness)~* known hypersensitivity, intolerance, or unresponsiveness to risperidone.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Intestinal Behçet's disease~* Patients with typical ulcer at ileocecal region~* Patients who have failed conventional treatment~Exclusion Criteria:~* Crohn's disease~* History of ileocecal resection~* History of tuberculosis (TB)~* Female subject who is pregnant or breast-feeding or considering becoming pregnant during the study

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): Adalimumab 160 mg at Week 0, 80 mg at Week 2 and 40 mg every other week (eow) starting at Week 4 to Week 50, subcutaneous injection. After Week 52, participants could continue the treatment with 40 mg eow until the day before approval of adalimumab for intestinal Behçet's disease in Japan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Supplementation With Soy Isoflavones in Asthma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ages 18-50, males and females~* Physician diagnosis of asthma; requires daily asthma medication~* Moderate persistent disease (NAEPP guidelines)~* FEV1 65 to 90% of predicted~* At least 12% increase in FEV1 15-30 minutes after inhaling 2-4 puffs of albuterol or positive methacholine challenge (20% fall in FEV1 at less than 8 mg/ml) - either of these can available from the previous 2 years~* Generally good health~Exclusion Criteria:~* Oral corticosteroid use within the past 3 months~* Use of high dose inhaled corticosteroids (greater than 500 mcg of fluticasone per day or greater)~* Current or former smoker (quit less than 6 months prior to study enrollment or greater than 10 pack years)~* Recent asthma exacerbation (within 6 weeks)~* Current consumption of soy isoflavone supplements~* Known adverse reaction to genistein, other phytoestrogens, or soy products~* Pregnant~* Unintentional weight loss of more than 10 pounds within the year~* Major or unstable medical condition~* Use of an investigational drug in the previous 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Progressed from VEG105192 study treatment~* Patient's VEG105192 was placebo~* Baseline has good organ function~Exclusion criteria:~* No brain metastasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- pazopanib arm (Type: EXPERIMENTAL): This was a single arm study, therefore no control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Estrogens in Lupus: Birth Control Pills

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* Unequivocal diagnosis of SLE~* Inactive disease or be stable on 0.5 mg/kg/day or less of predisone~* Must be between 18 and 39 years old if non-smoker~* Must be between 18 and 35 years old if smoker~Exclusion Criteria:~* Blood pressure \>145/95 on three occasions~* Deep vein, arterial thrombosis or pulmonary embolus~* GPL \>40; MPL \>40; APL \>50; dRVVT \>37 sec~* APL antibody syndrome ever~* Gynecologic or breast cancer~* Hepatic dysfunction or liver tumors~* Diabetes mellitus (NOT due to steroids) with vascular disease~* Congenital hyperlipidemia~* Complicated migraine~* Severe disease activity (SLEDAI \>12)~* Increase in SLEDAI \>2 points in 3 months~* Unexplained vaginal bleeding~* Use of estrogen (OCP) for \>1 month at any time after SLE diagnosis~* Present pregnancy~* Angina or MI due to APS~* Age \>35 yrs. for smokers; \>39 yrs. for nonsmokers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic Uncontrolled Pain That Required Stronger Opioid Therapy Than They Have Been Taking~* Histologically Confirmed Solid Cancer~* Aged Over 18 Years~* Admitted in a Palliative Cancer Care Unit~Exclusion Criteria:~* Uspected to Have Narcotic Abuse, Clinically Relevant CO2 Retention or Had an Active Skin Disease~* Inability to swallow oral medication, and impaired sensory or cognitive function~* Patients who had an active infection, uncontrolled central nervous system involvement, or on antitumor therapy of any kind

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Participants with chronic renal failure on hemodialysis for ≥ 3 months prior to randomization.~2. On intravenous epoetin alfa maintenance therapy continuously prescribed for a minimum of 8 weeks prior to randomization.~3. Four consecutive hemoglobin values with a mean ≥ 10.0 and ≤ 12.0 g/dL during the screening period~Exclusion Criteria~1. Females who are pregnant or breast-feeding.~2. Known intolerance to any erythropoiesis stimulating agent (ESA) or pegylated molecule or to all parenteral iron supplementation products.~3. Known bleeding or coagulation disorder.~4. Known hematologic disease or cause of anemia other than renal disease~5. Poorly controlled hypertension~6. Evidence of active malignancy within one year prior to randomization.~7. Temporary (untunneled) dialysis access catheter.~8. A scheduled kidney transplant~9. A scheduled surgery that may be expected to lead to significant blood loss.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginesatide (Type: EXPERIMENTAL): None
- Epoetin alfa (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Pain Management in Patients Undergoing Intramedullary Nail Fixation After Tibia and Femoral Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with tibial and femoral shaft fractures~2. Patients undergoing intramedullary nailing~3. Willing to participate in the protocol~Exclusion Criteria:~1. Chronic pain disorder (daily use of oral opioids)~2. Allergy or hypersensitivity to non steroid anti-inflammatory drug~3. Impaired renal, cardiac, or hepatic function~4. History of gastrointestinal bleeding or substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: Intravenous Ketorolac and oral acetaminophen (Type: EXPERIMENTAL): Group 1 will be composed of patients receiving the following standard pain control protocol: ketorolac 30 mg intravenous (IV) every 6 hours for patients younger than 70 years versus ketorolac 15 mg IV every 6 hours for patients older than 70 years, first dose will be administered 30 minutes preoperatively. An additional 1000mg of oral acetaminophen will be administered every 6 hours simultaneously regardless of the age group. Patients who determine pain to be unbearable and wish to opt out of the non-opioid group will receive may do so.
- Group 2: Intravenous Morphine and oral oxycodone (Type: ACTIVE_COMPARATOR): Group 2 will be composed of patients receiving the following pain control protocol: morphine 0.1 mg per kg intravenous every 6 hours with an additional oral oxycodone combined with acetaminophen 2 tabs every 6 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: (Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~History of recurrent abdominal pain with cramping (APC) for at least three months.~Recorded at least two episodes of APC of at least moderate intensity (i.e., 5 or above on a 0-10 point scale) lasting one hour in the eDiary during the run-in period.~Exclusion Criteria:~Experiencing daily episode of APC during Run-in period Active gastrointestinal disease during the past 12 months including malignancy, inflammatory bowel disease, celiac disease or complete or partial bowel obstruction and who have undergone major gastrointestinal surgery with the past 12 months (patients with history of appendectomy, cholecystectomy, bilateral tubal ligation and c-section within past 12 months are allowed in the study).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyoscine butylbromide (HBB) 20mg 1-5 tablets per episode (Type: ACTIVE_COMPARATOR): Patient to receive 1-5 tablets containing 20mg HBB per Abdominal pain associated with cramping (APC) episode
- Placebo (Type: PLACEBO_COMPARATOR): patient to receive a tablet identical to those containing HBB and take 1-5 tablets per episode

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete